Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved treatments, prompting the San Diego biotech to plot a submission to the FDA ...

While bone cancer is relatively rare – about 0.4% of all cancer deaths and 0.2% of all new cancer cases in the US in 2025 – it’s devastating, causing difficulty in moving limbs, bone fractures, and ...

Researchers have developed a magnetic nanomaterial that can kill bone cancer cells and support bone regeneration at the same time. The material heats up under a magnetic field to destroy tumors, while ...

Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate conformation. Much of this processing occurs in the endoplasmic reticulum ...